1,954 reports of this reaction
14.5% of all EPTINEZUMAB JJMR reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for EPTINEZUMAB JJMR, manufactured by Lundbeck Pharmaceuticals LLC. There are 1,954 FDA adverse event reports linking EPTINEZUMAB JJMR to DRUG INEFFECTIVE. This represents approximately 14.5% of all 13,519 adverse event reports for this drug.
Patients taking EPTINEZUMAB JJMR who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is a frequently reported adverse event for EPTINEZUMAB JJMR, accounting for a significant proportion of all reports.
In addition to drug ineffective, the following adverse reactions have been reported for EPTINEZUMAB JJMR:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 1,954 FDA reports for EPTINEZUMAB JJMR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 14.5% of all adverse event reports for EPTINEZUMAB JJMR, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking EPTINEZUMAB JJMR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.